30T announces interim results from Phase 2 tuberculosis trial

30T is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA).

30 Technology- EMA Approval to launch a Phase 1/2a trial in patients with Non-Cystic Fibrosis Bronchiectasis

30 Technology is thrilled to announce approval for our Phase 1/2a trial designed to evaluate the safety, tolerability, and efficacy of nebulised Nitric Oxide Formulations

30 Technology completes final patient dosing in its TB study in South Africa

30 Technology is excited to announce that we have successfully completed the final dosing for all participants enrolled in our Tuberculosis study based in South Africa.

30 TECHNOLOGY: DELIVERING THE FULL POTENTIAL OF THERAPEUTIC NITRIC OXIDE

30 TECHNOLOGY is developing nitric oxide-generating technologies
for a range of health care applications

Watch video